TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39405911

Group type: EXPERIMENTAL
Intervention: Metformin (MET)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Doxorubicin (DOX)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Doxorubicin (DOX) + Metformin (MET)
Number of subjects: 18
Study: 39405978

Group type: EXPERIMENTAL
Intervention: Spermidine trihydrochloride supplement at 40 mg/day
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 39406181

Group type: EXPERIMENTAL
Intervention: Virtual reality goggles (360° relaxing videos, 30 min per use, 3 days a week for 4 weeks)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Virtual reality goggles
Number of subjects: 44
Study: 39406392

Group type: EXPERIMENTAL
Intervention: iCer NIVO + IPI
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Postoperative iCav NIVO (1-5-10 mg)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: iCav NIVO plus IPI
Number of subjects: 42

Group type: COMPARATOR
Intervention: Historical pooled cohort of Belgian rHGG patients treated with anti-VEGF therapies
Number of subjects: 42
Study: 39406403

Group type: EXPERIMENTAL
Intervention: Bimekizumab 160 mg every 4 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 39406449

Group type: EXPERIMENTAL
Intervention: Short term intensive insulin therapy (SIIT) followed by linagliptin 5 mg/day for 48 weeks
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Short term intensive insulin therapy (SIIT) followed by metformin 1000 mg/day for 48 weeks
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Short term intensive insulin therapy (SIIT) followed by combination linagliptin plus metformin for 48 weeks
Number of subjects: 412

Group type: COMPARATOR
Intervention: Short term intensive insulin therapy (SIIT) followed by lifestyle modification alone for 48 weeks (control)
Number of subjects: 412
Study: 39406613

Group type: EXPERIMENTAL
Intervention: Nadofaragene firadenovec
Number of subjects: 32
Study: 39406630

Group type: EXPERIMENTAL
Intervention: U-SleepSQ model using 24/7 electroencephalography SubQ data
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: U-SleepSQ model
Number of subjects: 22
Study: 39406730

Group type: EXPERIMENTAL
Intervention: Nivolumab plus anlotinib hydrochloride
Number of subjects: 48
Study: 39407122

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided erector spinae plane block (ESPB)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Wound infiltration (WI)
Number of subjects: 80
Study: 39407194

Group type: EXPERIMENTAL
Intervention: NLR (Neutrophil-to-Lymphocyte Ratio)
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: PLR (Platelet-to-Lymphocyte Ratio)
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: Plateletcrit
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: Platelet count
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: NLR cutoffs
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: Markers of inflammation
Number of subjects: 443
Study: 39407204

Group type: EXPERIMENTAL
Intervention: Increased perceived threat of COVID-19
Number of subjects: 500

Group type: COMPARATOR
Intervention: Anxiety and depression (controlled for in analysis)
Number of subjects: 500
Study: 39407206

Group type: EXPERIMENTAL
Intervention: Bruxism patients (64)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Non-bruxism patients (64)
Number of subjects: 128
Study: 39407226

Group type: EXPERIMENTAL
Intervention: Elite endurance runners and elite sprinters
Number of subjects: 188

Group type: COMPARATOR
Intervention: Untrained individuals
Number of subjects: 188
Study: 39407230

Group type: EXPERIMENTAL
Intervention: Hypothermia at 33°C
Number of subjects: 600

Group type: COMPARATOR
Intervention: Normothermia (target < 37.8°C)
Number of subjects: 600
Study: 39407238

Group type: EXPERIMENTAL
Intervention: DIDE mobile application
Number of subjects: 24
Study: 39407247

Group type: EXPERIMENTAL
Intervention: MTA
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: ZOE
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: NeoMTA™
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Biodentine™
Number of subjects: 120
Study: 39407315

Group type: EXPERIMENTAL
Intervention: Magnesium sulphate (MgSO4) iontophoresis plus conventional physical therapy program
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: High-power pain-threshold ultrasound (HPPT-US) plus conventional therapy
Number of subjects: 75

Group type: COMPARATOR
Intervention: Conventional therapy only
Number of subjects: 75
Study: 39407325

Group type: EXPERIMENTAL
Intervention: mannitol-potentiated low-dose amikacin
Number of subjects: 90

Group type: COMPARATOR
Intervention: ceftriaxone or amikacin standard dose
Number of subjects: 90
Study: 39407334

Group type: COMPARATOR
Intervention: Treat-to-target-driven fixed dose retreatment strategy (usual care group) - retreated with fixed rituximab doses (1 × 1000 mg IV) in case of loss of disease control (DAS28-CRP ≥ 3.2)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Fixed interval disease-activity guided dose optimisation strategy (experimental group) - 24-weekly rituximab treatment with tapering doses: 1 × 1000 mg IV (maximal dose), 1 × 500 mg IV, and 1 × 200 mg IV (minimal dose)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Fixed interval disease-activity guided dose optimisation strategy (experimental group)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Treat-to-target-driven fixed dose retreatment strategy (usual care group)
Number of subjects: 134
Study: 39407365

Group type: EXPERIMENTAL
Intervention: Mechanical method using a rotary master apical file
Number of subjects: 60

Group type: COMPARATOR
Intervention: Chemomechanical method using an endoactivator to sonically agitate the endodontic irrigant
Number of subjects: 60
Study: 39407366

Group type: EXPERIMENTAL
Intervention: Postural and kinesthetic awareness sessions (experimental group B)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Routine physical therapy (control group A)
Number of subjects: 52
Study: 39407381

Group type: EXPERIMENTAL
Intervention: Isometric exercises
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Isotonic exercises
Number of subjects: 22
Study: 39407408

Group type: EXPERIMENTAL
Intervention: Nurse-led integrated care intervention
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 69
Study: 39407731

Group type: EXPERIMENTAL
Intervention: Novel Digital Ostomy Device
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 39407979

Group type: EXPERIMENTAL
Intervention: COVID-19 ARDS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-COVID-19 ARDS
Number of subjects: 0
Study: 39408038

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 39408203

Group type: EXPERIMENTAL
Intervention: Very Low-Calorie Ketogenic Diet (VLCKD) for 20 weeks
Number of subjects: 20
Study: 39408354

Group type: EXPERIMENTAL
Intervention: 2'-Fucosyllactose (3 g/d)
Number of subjects: 41
Study: 39408358

Group type: EXPERIMENTAL
Intervention: Montmorency Tart Cherry Powder supplementation with a purine-rich meal
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 39408601

Group type: EXPERIMENTAL
Intervention: Taldefgrobep alfa as an adjunct to SMN upregulators
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 39409993

Group type: EXPERIMENTAL
Intervention: Cancer Patient Empowerment Program (CancerPEP) without HRV biofeedback monitor
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Cancer Patient Empowerment Program (CancerPEP) with HRV biofeedback monitor
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Cancer Patient Empowerment Program (CancerPEP) for breast cancer subgroup
Number of subjects: 104

Group type: COMPARATOR
Intervention: Usual care without intervention (control group for future trial)
Number of subjects: 104
Study: 39410716

Group type: EXPERIMENTAL
Intervention: Potassium supplements (T3)
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Magnesium supplements (T2)
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Both magnesium and potassium supplements (T4)
Number of subjects: 290

Group type: COMPARATOR
Intervention: Control/placebo (T1)
Number of subjects: 290
Study: 39410736

Group type: EXPERIMENTAL
Intervention: ACP+ intervention
Number of subjects: 7
Study: 39410977

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Cognitive rehabilitation (Control)
Number of subjects: 24
Study: 39411184

Group type: EXPERIMENTAL
Intervention: Active iTBS targeting the right DLPFC
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Active iTBS targeting the left LPC
Number of subjects: 96

Group type: COMPARATOR
Intervention: Sham iTBS
Number of subjects: 96
Study: 39411190

Group type: EXPERIMENTAL
Intervention: Changes in the hypoattenuating region of the blend sign (CHB group)
Number of subjects: 183

Group type: COMPARATOR
Intervention: No changes in the hypoattenuating region of the blend sign (NHB group)
Number of subjects: 183
Study: 39411383

Group type: EXPERIMENTAL
Intervention: Morphine (0.05 mg/kg; i.v.) + oral pramipexole (0.25 mg)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Morphine (0.1 mg/kg; i.v.) + oral placebo
Number of subjects: 19
Study: 39411812

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg plus carboplatin-paclitaxel (four to six cycles) followed by pembrolizumab 400 mg (six cycles)
Number of subjects: 281

Group type: COMPARATOR
Intervention: Placebo plus carboplatin-paclitaxel (four to six cycles) followed by placebo (six cycles)
Number of subjects: 281
Study: 39411974

Group type: EXPERIMENTAL
Intervention: Intravenous secukinumab (Cosentyx®) at a dosage of 3 mg/kg every 4 weeks (q4w)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Intravenous secukinumab (Cosentyx®) at a dosage of 1.75 mg/kg every 4 weeks (q4w)
Number of subjects: 2
Study: 39411994

Group type: EXPERIMENTAL
Intervention: Noninvasive HPI
Number of subjects: 91

Group type: COMPARATOR
Intervention: Invasive HPI
Number of subjects: 91
Study: 39412495

Group type: EXPERIMENTAL
Intervention: High-Intensity Parenting Intervention (HIP)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Lower-Intensity Parenting Intervention (LIP)
Number of subjects: 106
Study: 39412509

Group type: EXPERIMENTAL
Intervention: Subcutaneous semaglutide 2.4 mg
Number of subjects: 800

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 800
Study: 39412613

Group type: EXPERIMENTAL
Intervention: Multi-task deep-learning model for automated segment-level coronary artery calcium scoring
Number of subjects: 1514
Study: 39412619

Group type: EXPERIMENTAL
Intervention: Controlled Administration Device (CAD)
Number of subjects: 3
Study: 39412628

Group type: EXPERIMENTAL
Intervention: Triptorelin pamoate 22.5 mg (day 1 and month 6)
Number of subjects: 66
Study: 39412672

Group type: EXPERIMENTAL
Intervention: Behaviorally designed intervention with gamification and social support
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (weekly updates only)
Number of subjects: 31
Study: 39412732

Group type: EXPERIMENTAL
Intervention: mySugr
Number of subjects: 28

Group type: COMPARATOR
Intervention: usual care (bolus calculator, five face-to-face visits)
Number of subjects: 28
Study: 39412778

Group type: EXPERIMENTAL
Intervention: iFR
Number of subjects: 1891

Group type: COMPARATOR
Intervention: FFR
Number of subjects: 1891
Study: 39412806

Group type: EXPERIMENTAL
Intervention: Upper-extremity approach (radial artery diagnostic access and upper-arm vein for temporary pacing lead placement)
Number of subjects: 238

Group type: COMPARATOR
Intervention: Lower-extremity approach (femoral artery diagnostic access and femoral vein for temporary pacing lead placement)
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Upper-extremity approach
Number of subjects: 238

Group type: COMPARATOR
Intervention: Lower-extremity approach
Number of subjects: 238
Study: 39412840

Group type: EXPERIMENTAL
Intervention: Enhanced health education intervention
Number of subjects: 20

Group type: COMPARATOR
Intervention: Basic health education alone
Number of subjects: 20
Study: 39412860

Group type: EXPERIMENTAL
Intervention: Multidisciplinary home-based rehabilitation program (32 sessions for physical therapy, 8 sessions for occupational therapy, 4 sessions for nutrition, 8 sessions for psychology, and 4 sessions for nursing and podiatry over 4 months)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Multidisciplinary home-based rehabilitation program
Number of subjects: 270
Study: 39412869

Group type: EXPERIMENTAL
Intervention: LIVIA 2.0 (active arm)
Number of subjects: 62

Group type: COMPARATOR
Intervention: LIVIA 1 (control arm)
Number of subjects: 62
Study: 39413050

Group type: EXPERIMENTAL
Intervention: Super-oxidized solution
Number of subjects: 102

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 102
Study: 39413203

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 39413305

Group type: EXPERIMENTAL
Intervention: PriCARE intervention (n = 92)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Waitlist control (n = 90)
Number of subjects: 182
Study: 39413339

Group type: EXPERIMENTAL
Intervention: Palbociclib
Number of subjects: 70
Study: 39413359

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR(BC)) program
Number of subjects: 0
Study: 39413375

Group type: EXPERIMENTAL
Intervention: Nivolumab with doxorubicin, vinblastine, and dacarbazine (N+AVD)
Number of subjects: 970

Group type: COMPARATOR
Intervention: Brentuximab vedotin with doxorubicin, vinblastine, and dacarbazine (BV+AVD)
Number of subjects: 970
Study: 39413376

Group type: EXPERIMENTAL
Intervention: Kidney transplantation from donors with HIV
Number of subjects: 408

Group type: COMPARATOR
Intervention: Kidney transplantation from donors without HIV
Number of subjects: 408
Study: 39413377

Group type: EXPERIMENTAL
Intervention: SBRT (36.25 Gy in 5 fractions over 1 or 2 weeks)
Number of subjects: 874

Group type: COMPARATOR
Intervention: Control radiotherapy (78 Gy in 39 fractions over 7.5 weeks or 62 Gy in 20 fractions over 4 weeks)
Number of subjects: 874

Group type: EXPERIMENTAL
Intervention: SBRT
Number of subjects: 874

Group type: COMPARATOR
Intervention: Control radiotherapy
Number of subjects: 874
Study: 39413735

Group type: EXPERIMENTAL
Intervention: Gemcitabine (1,000 mg/m²) plus toripalimab
Number of subjects: 0
Study: 39413989

Group type: COMPARATOR
Intervention: Online recruitment strategies
Number of subjects: 649

Group type: COMPARATOR
Intervention: Traditional recruitment strategies
Number of subjects: 649

Group type: EXPERIMENTAL
Intervention: Overall recruitment effectiveness
Number of subjects: 649

Group type: EXPERIMENTAL
Intervention: Reasons for ineligibility
Number of subjects: 649
Study: 39413990

Group type: EXPERIMENTAL
Intervention: CS + Fast (110 kcal of sucrose)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: CS + Slow (110 kcal of maltodextrin)
Number of subjects: 64

Group type: COMPARATOR
Intervention: CS- (0-kcal sucralose)
Number of subjects: 64
Study: 39414121

Group type: EXPERIMENTAL
Intervention: Parent-reported outcomes
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Parent communication strategies
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Parent and child self-report
Number of subjects: 110
Study: 39414223

Group type: COMPARATOR
Intervention: Fortified eggs (FE) - instructed to consume at least 12 FE/week; Control: nonegg supplemented diet - restricted to <2 eggs/week
Number of subjects: 140

Group type: COMPARATOR
Intervention: Time-restricted eating (TRE) - instructed to consume all calories within an 8-hour window; Control: usual care diet - advised to maintain current dietary habits
Number of subjects: 140
Study: 39414268

Group type: EXPERIMENTAL
Intervention: Therapist-guided internet-delivered behavioural activation (I-BA) for 10 weeks
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Self-guided internet-delivered behavioural activation (I-BA) for 10 weeks
Number of subjects: 215

Group type: COMPARATOR
Intervention: Treatment as usual (TAU) provided by regular mental health clinics
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: All interventions (therapist-guided I-BA, self-guided I-BA, TAU)
Number of subjects: 215
Study: 39414276

Group type: EXPERIMENTAL
Intervention: Standardised treatment including LLN dissection (LLND) after neoadjuvant treatment and TME surgery.
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Neoadjuvant treatment by trained radiation oncologists followed by TME surgery.
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Standardised treatment including LLND.
Number of subjects: 200
Study: 39414278

Group type: EXPERIMENTAL
Intervention: Healthy school lunch provided for 18 weeks
Number of subjects: 5

Group type: COMPARATOR
Intervention: Children bringing their own lunch from home
Number of subjects: 5
Study: 39414279

Group type: EXPERIMENTAL
Intervention: Proton pump inhibitors (PPIs) including omeprazole, esomeprazole, and pantoprazole
Number of subjects: 1264798

Group type: EXPERIMENTAL
Intervention: Proton pump inhibitors (PPIs)
Number of subjects: 1264798
Study: 39414282

Group type: EXPERIMENTAL
Intervention: Rock-climbers
Number of subjects: 363

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 363
Study: 39414286

Group type: EXPERIMENTAL
Intervention: Postpartum telephone support for lifestyle changes
Number of subjects: 466

Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 466
Study: 39414294

Group type: EXPERIMENTAL
Intervention: High-load strength training (2 weekly sessions for 12 weeks)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard care (low-intensity strength training and/or proprioceptive training)
Number of subjects: 100
Study: 39414298

Group type: EXPERIMENTAL
Intervention: Graded Repetitive Arm Supplementary Programme (GRASP) combined with Post-Rehabilitation Enablement Programme (PREP) for 6 weeks
Number of subjects: 72

Group type: COMPARATOR
Intervention: Post-Rehabilitation Enablement Programme (PREP) for 6 weeks
Number of subjects: 72
Study: 39414325

Group type: EXPERIMENTAL
Intervention: NG-350A (intravenous administration)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: NG-350A (intratumoral administration)
Number of subjects: 25
Study: 39414341

Group type: EXPERIMENTAL
Intervention: Videogame application for 8 weeks
Number of subjects: 28

Group type: COMPARATOR
Intervention: Weekly WhatsApp messages on healthy behaviours (Control)
Number of subjects: 28
Study: 39414374

Group type: EXPERIMENTAL
Intervention: Standard audit and feedback (AF) and educational summary (ES) intervention arm (n=1691)
Number of subjects: 5073

Group type: EXPERIMENTAL
Intervention: Educational summary (ES)-only arm (n=1691)
Number of subjects: 5073

Group type: COMPARATOR
Intervention: Control arm (n=1691)
Number of subjects: 5073
Study: 39414418

Group type: EXPERIMENTAL
Intervention: Once-weekly efanesoctocog alfa prophylaxis 50 IU/kg for 52 weeks (Arm A)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: On-demand efanesoctocog alfa 50 IU/kg for 26 weeks followed by 26 weeks once-weekly prophylaxis (50 IU/kg; Arm B)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Efanesoctocog alfa prophylaxis
Number of subjects: 159

Group type: COMPARATOR
Intervention: Pre-study treatment
Number of subjects: 159
Study: 39414623

Group type: EXPERIMENTAL
Intervention: Family-scout intervention
Number of subjects: 472

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 472
Study: 39414987

Group type: EXPERIMENTAL
Intervention: JNJ-42165279 (25 mg, twice-daily)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 39414998

Group type: EXPERIMENTAL
Intervention: Reduction in sedentary behavior by 1 hour/day
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group maintaining usual sedentary behavior habits
Number of subjects: 64
Study: 39414999

Group type: EXPERIMENTAL
Intervention: Digital mindset intervention focusing on adaptive mindsets
Number of subjects: 408

Group type: COMPARATOR
Intervention: No-intervention group
Number of subjects: 408

Group type: COMPARATOR
Intervention: Digital education intervention
Number of subjects: 408
Study: 39415093

Group type: EXPERIMENTAL
Intervention: Engagement in mental health services
Number of subjects: 20
Study: 39415117

Group type: EXPERIMENTAL
Intervention: Practical and Social Functioning scale (PSF)
Number of subjects: 562
Study: 39415149

Group type: EXPERIMENTAL
Intervention: High IPAQ category (n=137)
Number of subjects: 1270

Group type: COMPARATOR
Intervention: Moderate IPAQ category (n=995)
Number of subjects: 1270

Group type: COMPARATOR
Intervention: Low IPAQ category (n=138)
Number of subjects: 1270
Study: 39415181

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 51
Study: 39415182

Group type: EXPERIMENTAL
Intervention: Attachment-based family therapy (ABFT)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 142
Study: 39415279

Group type: EXPERIMENTAL
Intervention: Sinetrol
Number of subjects: 0
Study: 39415283

Group type: EXPERIMENTAL
Intervention: 12-week structured physical activity programme supervised by a sport medicine physician, preceded by three psychoeducation sessions on healthy eating habits.
Number of subjects: 64

Group type: COMPARATOR
Intervention: 12-week psychoeducation programme on physical activity, diet, and health risks of a sedentary lifestyle for a total of 8 sessions.
Number of subjects: 64
Study: 39415282

Group type: EXPERIMENTAL
Intervention: Preoperative immunonutrition (IN) for 7 days
Number of subjects: 232

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 232
Study: 39415344

Group type: EXPERIMENTAL
Intervention: Lotiglipron 80 mg
Number of subjects: 901

Group type: EXPERIMENTAL
Intervention: Lotiglipron 200 mg (five-step titration)
Number of subjects: 901

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 901

Group type: EXPERIMENTAL
Intervention: Lotiglipron (T2D cohort)
Number of subjects: 901
Study: 39415507

Group type: EXPERIMENTAL
Intervention: Adjuvant chemoradiation with lapatinib
Number of subjects: 681

Group type: COMPARATOR
Intervention: Adjuvant chemoradiation without lapatinib
Number of subjects: 681

Group type: EXPERIMENTAL
Intervention: High NLR
Number of subjects: 681

Group type: EXPERIMENTAL
Intervention: High ANC
Number of subjects: 681

Group type: EXPERIMENTAL
Intervention: High ALC
Number of subjects: 681
Study: 39415599

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study: 39415650

Group type: EXPERIMENTAL
Intervention: Adjunctive brexpiprazole (2–3 mg/day)
Number of subjects: 489

Group type: COMPARATOR
Intervention: Adjunctive placebo (brexpiprazole withdrawal)
Number of subjects: 489